Jet lag disrupts the body's internal clock, leaving travelers fatigued and sleep-deprived. Two peptides, Selank (a synthetic tuftsin analogue) and DSIP (Delta Sleep-Inducing Peptide), have drawn attention from researchers studying circadian rhythm repair without sedation. Russian investigators, particularly from the Khavinson school, have explored how these compounds might restore natural sleep architecture after transmeridian travel. Their work suggests distinct mechanisms: Selank may stabilize neurotransmitter balance, while DSIP could promote slow-wave sleep through hypothalamic pathways. This article examines the evidence for each, focusing on jet lag recovery and the goal of natural, non-sedative sleep.
The Russian Research School and Circadian Peptides
Professor Vladimir Khavinson and his colleagues at the St. Petersburg Institute of Bioregulation and Gerontology have pioneered peptide-based approaches to physiological regulation. Their studies often emphasize endogenous bioregulators that normalize, rather than force, bodily functions. In this context, DSIP was first isolated from rabbit cerebral venous blood during electrically induced sleep (Monnier 1977). Later, Khavinson's group investigated its effects on stress-induced circadian disruption in animal models, noting that DSIP administration could shift melatonin secretion patterns toward baseline (Khavinson 2002). Selank, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, emerged from work on tuftsin, a natural immunomodulator. Researchers found that adding a Pro-Gly-Pro tripeptide tail enhanced its stability and introduced anxiolytic properties without sedation (Ashmarin 2005). Both peptides have since been studied for their potential to recalibrate circadian rhythms after jet lag, though through different pathways.
Selank's Mechanism: Neurotransmitter Tuning Without Sedation
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide that modulates the expression of brain-derived neurotrophic factor (BDNF) and influences monoamine neurotransmitter systems. Russian studies indicate that Selank increases serotonin and dopamine levels in brain regions associated with circadian control, such as the suprachiasmatic nucleus (SCN) (Seredenin 2009). This effect is thought to stabilize mood and reduce anxiety, which often accompany jet lag. Unlike benzodiazepines, Selank does not bind to GABA-A receptors directly. Instead, it appears to enhance the efficiency of endogenous inhibitory signaling, perhaps by altering the expression of GABAergic receptor subunits (Andreeva 2012). For circadian repair, this means Selank may help the SCN re-entrain to a new light-dark cycle without causing drowsiness. Animal models of phase shift show that Selank-treated rats adapt more quickly to a 6-hour advance in light cycle, with normalized corticosterone rhythms (Kozlovskaya 2010). Human studies are limited, but a small trial on shift workers found that Selank improved subjective sleep quality and reduced fatigue after night shifts (Zozulya 2008). The lack of sedation is a key advantage for travelers who need to function upon arrival.
Except, and this matters, Selank's effects on sleep architecture are not fully characterized. While it reduces anxiety-related sleep latency, it may not directly increase slow-wave sleep (SWS) duration. For jet lag, where deep sleep is often fragmented, this could be a limitation. A comparison with DSIP, which is more directly linked to SWS promotion, becomes relevant. Our earlier article on Selank vs DSIP for circadian resynchronization after shift work noted that Selank's anxiolytic profile might be more suited to eastward travel, where difficulty falling asleep is common. Westward travel, with its early morning awakenings, might benefit more from a peptide that deepens sleep.
DSIP: Promoting Slow-Wave Sleep Through Hypothalamic Pathways
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide that was originally identified for its ability to induce sleep in rabbits. Subsequent research revealed that DSIP is not a classical sedative; it does not cause rapid sleep onset but rather facilitates the natural transition into SWS (Schoenenberger 1984). Khavinson's group demonstrated that DSIP administration in rats subjected to jet lag protocols restored the normal circadian rhythm of slow-wave activity, possibly by modulating the release of growth hormone-releasing hormone (GHRH) from the hypothalamus (Khavinson 2006). This is significant because GHRH is a key promoter of SWS, and its secretion is often blunted after time zone shifts. DSIP may also interact with the corticotropin-releasing hormone (CRH) system, reducing the stress-induced hyperarousal that exacerbates jet lag (Graf 1996).
In human studies, DSIP has shown mixed results. A double-blind trial on insomniacs found that DSIP improved sleep efficiency and increased SWS without affecting REM sleep (Schneider-Helmert 1986). However, other studies reported no significant benefit over placebo in healthy subjects. For jet lag specifically, a small study on airline personnel suggested that DSIP reduced daytime sleepiness and improved cognitive performance after long-haul flights (Bes 1996). The peptide's short half-life in plasma (minutes) raises questions about its practical use, though intranasal formulations have been explored to enhance bioavailability. Our analysis of Tesamorelin vs DSIP for GH-mediated slow-wave sleep enhancement highlighted that DSIP's SWS-promoting effects might be more consistent when combined with a GHRH agonist, but for jet lag, the goal is often a single intervention that supports natural sleep.
Comparative Evidence: Jet Lag Recovery and Sleep Quality
Direct comparisons between Selank and DSIP for jet lag are scarce in the literature. However, indirect evidence from circadian disruption models allows some inferences. A study by Anisimov (2012) on Epitalon, another Khavinson peptide, noted that DSIP co-administration enhanced the resynchronization of activity rhythms in aged rats. Selank was not tested in that paradigm, but its effects on BDNF and serotonin suggest a complementary role in mood stabilization during adaptation. For travelers, the choice may hinge on the primary symptom: anxiety-driven insomnia (favoring Selank) versus fragmented deep sleep (favoring DSIP).
One must consider the temporal pattern of administration. Selank's anxiolytic effect appears within 15 to 30 minutes after intranasal delivery and lasts several hours, making it suitable for pre-sleep use at the destination. DSIP, when given intravenously, has a rapid onset but brief duration; intranasal DSIP may have a more prolonged effect, though data are limited. Neither peptide is associated with morning hangover or tolerance development in animal studies, a critical advantage over conventional hypnotics. Yet, the lack of large-scale clinical trials means that individual responses may vary widely.
Open Questions and Future Directions
Despite decades of research, fundamental questions remain. The exact receptor for DSIP has not been definitively identified, though some evidence points to a G-protein-coupled receptor in the hypothalamus. Selank's interaction with the SCN is better characterized, but its effects on peripheral clocks in liver or muscle are unknown. For jet lag, where desynchrony between central and peripheral clocks contributes to malaise, a peptide that targets both could be ideal. Combining Selank and DSIP might theoretically address anxiety and deep sleep simultaneously, but no studies have tested this. Another open area is the role of age: older travelers often experience more severe jet lag, and peptides like Epitalon have been studied for age-related circadian decline (Khavinson 2011). Whether Selank or DSIP offers greater benefit in this population is unclear.
Finally, the regulatory landscape complicates access. In many countries, these peptides are available only for research purposes. The long-term safety of repeated use for frequent travelers has not been established. While Russian literature reports no serious adverse events in short-term studies, the absence of data on chronic administration warrants caution. For those seeking natural sleep without sedation, the promise of Selank and DSIP lies in their physiological mechanisms, but the evidence base remains largely preclinical and observational.
Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.